Company Overview and News
Nov 29, 2017 (LBO) – Aitken Spence won the coveted ‘Best Corporate Citizen Sustainability Award 2017’ an annual event organized by the Ceylon Chamber of Commerce, the country’s premier business chamber to recognize sustainable champions of the local corporate world.
July 24, 2017 (LBO) – Sri Lankan Government ministers, opposition parliamentarians and advisers will discuss current national challenges faced by the country and possible solutions for those issues at the eighth and the last session of the Sri Lanka Economic Summit 2017.
(PRESS RELEASE) – Sri Lanka’s urgent need to execute critical reforms and build sound institutions to propel the nation’s economic growth will come under discussion at the upcoming Sri Lanka Economic Summit 2017.
Dr. Arvind Subramanian, the Chief Economic Adviser of the Government of India, will attend as the keynote speaker of the Sri Lanka Economic Summit 2017 inaugural session.
Dr. Arvind Subramanian, the Chief Economic Adviser of the Government of India will attend as the keynote speaker of the Sri Lanka Economic Summit 2017 inaugural session.
July 03, 2017 (LBO) – The Importance of Sri Lankan businesses aligning its growth plans with greener practices to help develop a ‘sustainable era,’ will be discussed at the upcoming Sri Lanka Economic Summit 2017.
Fundsmith Emerging Equities Trust plc (the "Company") today announces audited results for the year ended 31 December 2016
Feb 22, 2017 (LBO) – Profits at Nestlé Lanka, a unit of a Swiss-based food group, rose 34 percent to 860 million rupees in the December 2016 quarter from a year earlier.
Jan 14, 2017 (LBO) – Nestlé Lanka layed the foundation stone for a new manufacturing facility at its factory in Pannala, Kurunegala, as commitment to strengthen the local dairy and coconut industries.
Nestlé Lanka’sManaging Director, Shivani Hegdestated: “The steady performance of our company is a result of the trust consumers place in our products, and the skills and commitment of our people. We have once again reaffirmed our position as a leading and respected company, committed to enhancing the quality of life of the people of Sri Lanka, through our strong brands and rural development initiatives.
Reuters – Sri Lankan shares closed at a more than two-week high led by large-cap beverages stocks while foreign investors picked up beaten down counters ahead of the national budget scheduled on Nov. 10.
Reuters – Sri Lankan shares fell on Friday from a near two-week high hit in the previous session as investors waited for cues from the national budget scheduled on Nov. 10.
Reuters – Sri Lankan shares closed Thursday at a near-two week high, helped by gains in blue chips and as foreign investors picked up beaten down stocks.
Reuters – Sri Lankan shares extended losses for a third straight session to close Tuesday at a fresh three-month low as investors shrugged off the central bank’s decision to keep rates unchanged.
Nov 01, 2016 (Reuters) – Sri Lankan shares extended losses for a third straight session to close Tuesday at a fresh three-month low as investors shrugged off the central bank’s decision to keep rates unchanged.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...